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Abstract
Technical advances in lipidomic analysis have generated tremendous amounts of quantitative lipid molecular species data,
whose value has not been fully explored. We describe a novel computational method to infer mechanisms of de novo lipid
synthesis and remodeling from lipidomic data. We focus on the mitochondrial-specific lipid cardiolipin (CL), a polyglycerol
phospholipid with four acyl chains. The lengths and degree of unsaturation of these acyl chains vary across CL molecules,
and regulation of these differences is important for mitochondrial energy metabolism. We developed a novel mathematical
approach to determine mechanisms controlling the steady-state distribution of acyl chain combinations in CL . We analyzed
mitochondrial lipids from 18 types of steady-state samples, each with at least 3 replicates, from mouse brain, heart, lung,
liver, tumor cells, and tumors grown in vitro. Using a mathematical model for the CL remodeling mechanisms and a
maximum likelihood approach to infer parameters, we found that for most samples the four chain positions have an
independent and identical distribution, indicating they are remodeled by the same processes. Furthermore, for most brain
samples and liver, the distribution of acyl chains is well-fit by a simple linear combination of the pools of acyl chains in
phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylglycerol (PG). This suggests that headgroup
chemistry is the key determinant of acyl donation into CL, with chain length/saturation less important. This canonical
remodeling behavior appears damaged in some tumor samples, which display a consistent excess of CL molecules having
particular masses. For heart and lung, the ‘‘proportional incorporation’’ assumption is not adequate to explain the CL
distribution, suggesting additional acyl CoA-dependent remodeling that is chain-type specific. Our findings indicate that CL
remodeling processes can be described by a small set of quantitative relationships, and that bioinformatic approaches can
help determine these processes from high-throughput lipidomic data.
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isoforms, which may be sn-1/sn-2 as well as acyl chain selective [6].
Characterization of lipid remodeling mechanisms is crucial to
understanding the functional roles of lipids in biological systems.
Advances in mass spectrometry now allow for the highthroughput analysis of the cellular lipidome, which is comprised
of numerous lipid classes as well as signaling intermediates [7].
The multidimensional mass spectrometry based shotgun lipidomics (MDMS-SL) approach is capable of simultaneously analyzing
hundreds to thousands of lipid molecular species, providing
tremendous amounts of data that can be used to infer mechanisms
of lipid biosynthesis and remodeling in diseased and normal states
[7]. However, bioinformatic tools and models to interpret MDMSSL data are sparse [8,9]. The further development of computational approaches to mechanistically analyze lipidomic data would
be extremely valuable, in particular for analysis of cardiolipin (CL,
1,3-diphosphatidyl-sn-glycerol), a key polyglycerolphospholipid

Introduction
Phospholipids play a crucial role in biological systems. They act as
key components in membrane physiology, bioenergetics, cellular
recognition, and signal transduction [1–3]. While the phospholipid de
novo biosynthesis pathway (the Kennedy pathway) is relatively well
understood, there is still much to know about the remodeling
pathway (the Lands cycle) [4–6]. The Lands cycle involves the
deacylation/reacylation of existing cellular phospholipids to create
new molecular species. Phospholipases, such as PLA1 and PLA2,
remove existing acyl chains to generate lysophospholipids. Various
transacylases or acyltransferases then reacylate the lysophospholipid
with a donor acyl chain, changing phospholipid architecture, which
provides a platform for numerous and diverse functional roles.
Remodeling processes could in principle be complex, as there are an
abundance of acyltransferase, transacylase, and phospholipase
PLoS ONE | www.plosone.org
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tumor (EPEN); VM derived stem cell tumor VM-NM1; and two
microgliomas (VM-M2 and VM-M3). Tumors were grown in vivo
and cell cultures in vitro [28,29]. Two additional cell lines, astrocyte
(non-tumorigenic) and BV2 (microglia), were used as controls. We
also analyzed B6 mouse tissues from heart, lung, and liver. For
each sample, the mass content and distribution of lipid molecular
species (CL, PC, PE, PG) were quantified, with acyl CoA
additionally measured for the B6 brain, heart, lung, and liver
samples (All raw data are in Table S1). The sn-1 and sn-2 acyl
chain designations of diacyl phospholipids (PC, PE, and PG) were
determined by MDMS-SL analysis [30]. In general, CL profiles
are consistent in replicates of a sample, but are diverse among
different samples and tissues. Figure 1 shows a comparison of the
samples B6 brain mitochondria, EPEN brain tumor mitochondria,
and B6 heart mitochondria. The data suggest wide variations in
lipid synthesis and remodeling processes across samples.

critically involved in energy metabolism, apoptosis, and membrane integrity [10].
CL is unique among phospholipids because it contains four fatty
acid (FA) chains and is exclusively found in the inner mitochondrial membranes of eukaryotes [10,11]. CL molecular species vary
dramatically during development and among tissues. Abnormalities in these profiles have been associated with changes in cellular
bioenergetics and diseases, including Barth syndrome, diabetes,
heart failure, and cancer [11–16]. The distribution and arrangement of molecular species are thought to be achieved by acyl
remodeling processes and have functional significance. Because
the potential variety of CL species is extremely large (N4 positional
permutations are possible with N types of fatty acids), CL
distributions and identified molecular species have been difficult
to analyze in numerous cases [15]. A systematic computational
approach is in great need for the analysis and understanding of CL
regulation.
CL is de novo synthesized from the condensation of phosphatidylglycerol (PG) and cytidine diphosphate-diacylglycerol (CDPDAG). The four acyl chains of this immature CL are largely
comprised of shorter and saturated or mono/diunsaturated acyl
chains [12,17,18]. Immature CL species then undergo extensive
remodeling. This can be achieved by an acyl CoA dependent
deacylation-reacylation cycle, or via transacylation using acyl
chains from the sn-2 position of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) [10]. A limited number of
enzymes involved in CL remodeling, such as CoA:lysocardiolipin
acyltransferase (ALCAT1), monolysocardiolipin acyltransferase
(MLCL AT), tafazzin, and calcium-independent phospholipase
A2 (iPLA2) are known, though the specificities of these enzymes
are not clear. There may also be many other remodeling enzymes
yet to be discovered [18–23], and heterogeneity of lipids within the
membrane may affect their activity [24].
Previously, we observed that the distribution of CL in the
C57BL mouse (B6) brain could be qualitatively explained by a
simple steady state model for CL remodeling [12,25]. The model
assumed random acyl chain incorporation into CL from a pool of
PC (sn-2), PE (sn-2), and PG acyl chains, with each of the four CL
chain positions assumed to be independently and identically
remodeled [26]. Although the model was able to closely fit CL
profiles for the mouse B6 brain, the model has not been formally
described and it is not known whether the behavior is general for
other tissues and diseased states.
In this work, we introduce a rigorous approach to systematically
determine the CL remodeling mechanism in any sample at steady
state. Using high throughput MDMS-SL data and a maximumlikelihood approach, we analyze 18 types of samples, from mouse
brain, heart, lung, liver, tumor cells, and tumors grown in vitro.
Improving on the assumptions of the simple model above, we built
a two-step process to separately answer for any sample: whether
the four chain positions of CL are independently and identically
remodeled; and how the acyl donors (PC, PE, PG, and acyl CoA)
contribute to CL fatty acid composition. Our method provides a
fast and informative approach for testing hypotheses about CL
remodeling mechanisms.

Testing of the Independent and Identical Distribution
Model
Our MDMS-SL procedure is capable of detecting more than
100 mass peaks of CL, each containing tens to hundreds of
possible CL isomers. Given the potential complexity of processes
affecting these CL species, we first analyzed the data from the
perspective of CL fatty acid chain concentrations, an approach
that reduces the dimensionality of the problem. As an initial
question, we investigated whether the four acyl chain positions of
CL are independently and identically remodeled. To test this, we
built an ‘‘Independent and Identical Distribution’’ (IID) model, in
which the relative frequency of a CL isomer is the product of the
probabilities of its four fatty acid chains (Methods, Equation 1).
The probability of a CL molecular species is the sum over all
isomers with the same number of total carbons and double bonds
(Methods, Equation 2). The FA distribution at the CL chain
positions, {PCL(a1), PCL(a2), …, PCL(an)} (ai are chain types found
among acyl donors PC sn-2, PE sn-2, PG, and acyl CoA), is
predicted by minimizing the error between the predicted and
observed CL molecular species distribution (Methods, Equation 3).
If IID behavior is consistent with the remodeling processes within
a sample, there should exist a FA distribution that can reproduce
the experimentally observed CL profile when Equation 1 is
applied.
Table 1 shows the least error and Pearson correlation coefficient
between the observed and optimally fit CL distribution. 13/14
mouse brain samples yield r.0.7. A second set of B6
measurements for brain, heart, lung, and liver also yield r.0.9.
The results suggest that in general, the four chain positions of CL
are independently and identically remodeled. To test the
robustness of the IID model, we performed four-fold cross
validation. The correlation coefficients in the cross-validation
were still strongly positive, though somewhat lower than for the
original data. This is not unexpected since each CL peak contains
information about only a few FA chains, and the cross-validation
uses only subsets of the peaks at a time. However all samples and
tissues achieved much higher correlation coefficients compared to
random label-permuted data (t-test p-value,0.05) indicating that
the IID model could accurately describe CL remodeling behavior.
The observed and optimal predicted CL distributions are given for
each sample in Table S2.
The predicted FA compositions of CL for each tissue are shown
in Figure 2 organized into clusters. According to our inference the
predominant FA in mouse brain is 18:1 (,48%). This is in
contrast to heart, liver and lung, for which 18:2 is the predominant
component (,70%). However, 18:1 is reduced in tumor samples,
in particular lower in VM-M2 vitro, VM-M3 vivo, and VM-M3

Results
Characterization of CL profiles across samples
Highly purified mitochondrial lipidomic data were obtained
from [12,27]. 14 mouse brain samples were analyzed, including
two normal strains C57BL/6J (B6) and VM/Dk (VM, which has a
210-fold increase in spontaneous brain tumor formation) [17]; B6
derived astro- cytoma tumor (CT-2A) and ependymoblastoma
PLoS ONE | www.plosone.org
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Figure 1. CL profiles are similar within biological replicates, but vary among samples/tissues. CL species are labeled along the x-axis by
mass/charge ratio (m/z), and the y- axis shows MDMS-SL measured concentrations. C57BL/6J (B6) mouse brain mitochondria (A), EPEN brain tumor
mitochondria (B), and B6 heart mitochondria (C) are shown as examples. The three replicates of each sample have similar CL distributions, but the
three tissues have distinct CL profiles.
doi:10.1371/journal.pone.0021170.g001

parameters indicate the relative contributions of each lipid class to
CL FA composition in steady state. For each sample, we then
searched for optimal parameter values that could explain the CL
acyl chain composition. Inferred CL acyl compositions and
experimental compositions in acyl donors are in Table S3. We
successfully found weight parameters for 11/14 mouse brain
samples with strong correlation coefficient (r.0.7) and significant
p-values (p,0.05) (Table 2). We also investigated the proportional
incorporation model with an additional acyl CoA weight
parameter for the heart, lung, liver, and additional B6 brain
sample, for which experimental acyl CoA distributions were
available. Among these tissues, liver and brain showed a good fit
(r.0.7) with the proportional incorporation model. Thus the
simple proportional incorporation model describes CL remodeling
in most tissues, despite the varying CL profiles in different
samples/tissues. This suggests that PC and PE transacylation
remodeling has little chain specificity within each class. In brain
and liver, transacylation is the dominant remodeling process, as
the inferred acyl CoA contribution is zero.
In 10/18 samples, PC had the largest contribution to the CL
acyl chain compositions. PE had the largest contribution in only
1/18 samples, and it had the lowest contribution in 13/18. For the
four B6 tissues, our inference suggests that acyl CoA is most
relevant in heart.

vitro. We also observed that the level of 16:0 is elevated in tumor
samples and cell cultures (.10%), compared to that in the B6 and
VM brain samples (,2%).

Proportional Incorporation of Acyl Chains from Acyl
Donors
To investigate the formation of acyl chain compositions in CL,
we then tested a ‘‘proportional incorporation’’ model which is a
refinment of the IID model. The proportional incorporation
hypothesis is that that fatty acid incorporation rates are controlled
by the head group of the donor class (PC, PE, PG or acyl CoA)
and that FAs within an acyl donor class are indistinguishable to the
remodeling enzymes. Under such a mechanism FAs would be
incorporated into CL proportionally to their prevalence in the
donor class. If this hypothesis is correct, the number of parameters
in the CL remodeling system can be reduced to the number of acyl
donor classes.
For the brain samples, we investigated a model with weight
parameters WPC, WPE, and WPG (Methods, Equation 6). These

Table 1. The independent and identical distribution model
successfully predicts CL distributions.

Deviations from the Proportional Incorporation Model
Sample

Error

Pearson
Correlation

Pearson Correlation
in cross validation (p-value)

BV2 vitro

0.0088

0.8465

B6

0.0010

0.9845

0.4960.17 (0.0032)
0.9660.01 (4.0E-05)

CT2A vitro

0.0053

0.9158

0.7760.04 (1.4E-05)

Astrocyte vitro

0.0061

0.9206

0.4660.27 (0.018)

EPEN vitro

0.0043

0.9205

0.7560.03 (0.0018)

VM M2 vitro

0.0067

0.8451

0.6560.05 (0.0075)

VM M3 vivo

0.0158

0.7416

0.3660.09 (0.0012)

VM M3 vitro

0.0192

0.5804

0.3160.09 (0.0068)

VM NM1 vivo

0.0126

0.8828

0.3660.10 (0.0031)

VM NM1 vitro

0.0059

0.8908

0.7360.12 (0.00037)

VM

0.0143

0.8437

0.6660.09 (0.00019)

EPEN vivo

0.0080

0.8736

0.5860.12 (0.00062)

VM M2 vivo

0.0150

0.7722

0.6060.06 (0.00034)

CT2A vivo

0.0213

0.7245

0.3960.20 (0.019)

B6 brain

0.0014

0.9745

0.9160.01 (4.0E-06)

B6 heart

0.0007

0.9969

0.7860.16 (0.00054)

B6 lung

0.0030

0.9813

0.9360.01 (9.0E-06)

B6 liver

0.0002

0.9997

0.9960.00 (3.6E-08)

For samples where the proportional incorporation model failed
to explain the CL profile (VM-M3 vivo r = 20.1189, VM-M3
vitro r = 0.1829, VM-M2 vitro r = 0.4711, B6 heart r = 0.5069, B6
lung r = 0.5490), a number of explanations are possible. One
possibility is that an additional remodeling enzyme has been
utilized, altering the selectivity on chain types within a donor class.
In order to gain insight into which individual chain types are
under selection, we plotted FA composition residuals in the fit to
the proportional incorporation model (Figure 3). A positive
residual indicates that there is an excess of the chain in CL over
that predicted by the proportional incorporation model, i.e. a
remodeling enzyme may favor that chain type, and vice versa for
negative residuals. In the VM-M3 vivo and VM-M3 vitro samples,
16:0, 18:0 and 22:5 are favored in CL and 18:1 is disfavored. 18:2
is highly favored in B6 heart, lung, and liver, but not in brain.
16:0, 20:4 and 22:6 are slightly disfavored across the four tissues.
This residuals approach may be useful for understanding the
behavior of remodeling enzymes in genetic perturbations.
We also calculated the pair-wise correlation (R2) of residuals,
and hierarchically clustered chain types. As shown in Figure 4, we
found a group of chains {16:0, 18:1, 22:4} that cluster with one
another. This suggests that these chain types respond to the same
selective remodeling enzyme.

Quality of fit was assessed by squared-error between the fit and observed CL
distributions (column 2) as well as the Pearson correlation r of the fit and
observed CL data (column 3). 17/18 samples show r.0.7. The 4th column
shows Pearson correlation of the fit and observed CL distributions in four-fold
cross-validation (mean 6 standard deviation). P-values compare the crossvalidation correlation values to correlations calculated on CL data with the
labels randomly permuted (1-tail t-test). All samples achieved p-value ,0.05
indicating that the IID model could correctly describe the CL remodeling
system.
doi:10.1371/journal.pone.0021170.t001

PLoS ONE | www.plosone.org

Discussion
We have presented a novel, powerful computational method to
infer CL remodeling mechanisms from MDMS-SL data, which
we expect to be critical for understanding CL metabolism. New
mechanistic inference methods are of great importance since
lipidomic data, such as those in the LIPID MAPS projects [31–
33], are becoming increasingly abundant [34,35]. We focused on
4
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Figure 2. Comparison of CL FA compositions between 14 mouse brain samples (A) and 4 B6 mouse tissues (B). 18:1 is predominant in
brain (,40%), while its percentage is reduced in some tumor samples (e.g. VM-M2 vitro, VM-M3 vivo VM-M3 vitro). 18:2 is predominant in heart, lung,
and liver (,70%).
doi:10.1371/journal.pone.0021170.g002

characterizations of lipid pathways, such as the relative
concentrations of lipid classes [36] or signal transduction leading
to lipid changes [37]. Our focus on CL allowed us to investigate a
mechanistic model having a very small number of fit parameters,

synthesis and remodeling primarily within one class of lipids, CL,
taking advantage of the accuracy of MDMS-SL identification of
individual CL molecular species. In contrast, prior lipid
computational analyses have tended to focus on broader
PLoS ONE | www.plosone.org
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Table 2. Proportional incorporation model: inferred remodeling parameters and performance.

Sample

WPG

WPC

WPE

WAC

Pearson

p-value (Pearson)

Error

p-value (Error)

BV2 vitro

0.4471

0.3021

0.2508

-

0.8608

0.0132

0.052

0.0154

B6

0

1

0

-

0.8936

0.0024

0.0494

0.0024

CT2A vitro

0

1

0

-

0.9117

0.0041

0.0361

0.0038

Astrocyte vitro

0.0956

0.9044

0

-

0.8868

0.0064

0.0538

0.0075

EPEN vitro

0.2767

0.7128

0.0105

-

0.9072

0.0012

0.0304

0.0008

VM M2 vitro

0.3741

0.3641

0.2619

-

0.4711

0.1468

0.1089

0.2433

VM M3 vivo

0

0.7419

0.2581

-

20.1189

0.8255

0.2201

0.9722

VM M3 vitro

0

0.4694

0.5306

-

0.1829

0.4544

0.1572

0.6088

VM NM1 vivo

0.2284

0.7716

0

-

0.9428

0.0002

0.0451

0.0016

VM NM1 vitro

0.06

0.94

0

-

0.8619

0.0143

0.0464

0.0091

VM

0.4823

0.481

0.0367

-

0.7726

0.0143

0.1105

0.0111

EPEN vivo

0.4261

0.3887

0.1852

-

0.9384

0

0.0258

0

VM M2 vivo

0.5701

0

0.4299

-

0.9249

0.0004

0.0211

0.0002
0.0029

CT2A vivo

0.6631

0.0262

0.3108

-

0.8498

0.0038

0.0532

B6 brain

0.2869

0.7131

0

0

0.8893

0.0042

0.0415

0.0039

B6 heart

0

0.2212

0

0.7788

0.5069

0.2267

0.3358

0.2313

B6 lung

0

1

0

0

0.5490

0.1724

0.2624

0.1647

B6 liver

0

1

0

0

0.7859

0.0157

0.2889

0.0131

The optimal remodeling weights inferred via the proportional incorporation model are given for each sample for PC, PE, and PG, as well as for acyl CoA for the four
tissues where acyl coA data were available. The quality of fit was assessed by Pearson correlation r and squared-error between the fit and observed CL acyl compositions
(columns 6 and 8). Most samples were successfully fit by the proportional incorporation model (r.0.7). P-values were assessed by comparing to results for labelpermuted PC, PE, PG, and acyl CoA FA data (columns 7 and 9).
doi:10.1371/journal.pone.0021170.t002

which enabled us to robustly determine and cross-validate the
remodeling behavior in each sample.
Although CL displays tissue- and sample-specific distributions,
17/18 samples can be explained by the IID model. The proportional
incorporation model also fits 11/14 brain samples as well as the extra
B6 brain and liver samples, which is surprising given the model’s
simplicity. The success of the proportional incorporation model
suggests that in these tissues, the headgroups on acyl donors are the
main determinants of contribution to CL, rather than selectivity on
individual acyl chains. This is consistent with previous studies
indicating that the activities of remodeling enzymes such as PLA2
are determined by interactions on the bilayer surface rather than the
hydrophobic interior [38]. We also observe that PC in general
contributes more to CL than the other donor classes. Although the
mechanism for this is unclear, the classical surface dilution model
[24] suggests this may be an indication of domains within the
mitochondrial membrane of greater PC concentration, to which
remodeling enzymes may bind more easily. If there is selectivity on
the acyl chains, we speculate this may more commonly arise within
acyl CoA-related mechanisms. This is because the proportional
incorporation model works well even for many tissues for which acyl
CoA data were not available, This is consistent with PC and PE
contributing proportionally while acyl CoA is subject to more
specific regulation.
Interestingly, when we did observe deviation from the IID
behavior, these deviations had certain regularities. For example,
the CL peaks at 80:14 and 80:15 are consistently underestimated
in the BV2 vitro, VM M3 vitro, VM, and CT2A vivo samples (Figure
S1). The regularity of such deviations suggests there are
remodeling mechanisms that can distinguish the four positions
or which involve positional dependencies.
PLoS ONE | www.plosone.org

One simple way the chain positions could be distinguished is by
their sn-1 or sn-2 chemistry. We examined this by modifying the
IID model to an ‘‘independent and differential distribution’’ (IDD)
model that distinguishes sn-1 vs. sn-2 positions. However, this
modification provided little improvement in the fit. Only the VMNM1 vivo sample showed significant improvement (p-value ,0.05;
see Methods). This suggests that the unusual peaks at 80:14 and
80:15 are controlled by dependencies between positions, rather
than independent but differential behavior. This unimportance of
sn-1/sn-2 chemistry is surprising given that remodeling reactions
acting on diacyl phospholipids (PC, PE, PG, PI) have a bias for the
sn-2 position [39].
A minor caveat to our CL analysis is that it is based on the
concentrations of CL peaks as defined by the number of carbons and
double bonds among the acyl chains. Some lipidomic measurement
methods such as MDMS-SL provide additional information about
species distributions within each peak. Such information is irregular
and with different uncertainties across peaks, making it difficult to use,
but future methods may benefit from it.
Also, the model we have described here pertains to steady-state
behavior. This is appropriate since all of the samples we have analyzed
are under steady-state conditions. Therefore enzyme specificities
impact our model as they would affect equilibrium constants in typical
chemical systems (see Methods). Parameter inference for the dynamics
of remodeling is a valuable future goal, and we have previously
described software for simulating dynamic cardiolipin remodeling
[27]. However, optimal solution of the dynamic problem is beyond the
scope of this paper, as it requires experimental timecourse data and is
also a more challenging statistical inference problem.
Because of the tradeoff between complexity and robustness of
the inferred model [40], we have studied simplified models which
6
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Figure 3. FA residuals reveal potential enzyme selectivity. The y-axis shows the residual between the FA composition best describing the CL
data and the fit to this FA composition by the proportional incorporation model. A positive residual suggests enzyme preference. Box statistics are
shown for 14 brain samples (A) and 4 B6 mouse tissues (B) with median and 25th and 75th percentiles.
doi:10.1371/journal.pone.0021170.g003

The samples were C57BL/6J (B6) and VM/Dk (VM) inbred mice;
an astrocytoma (CT-2A) and an ependymoblastoma (EPEN) that
are chemically induced from syngeneic B6 brain; two microgliomas (VM-M2 and VM-M3) and a stem cell tumor (VM-NM1)
that arose spontaneously from the syngeneic VM brain; and two
brain cell lines: astrocyte (non-tumorigenic) and BV2 (microglia).
For each of these brain and brain tumor samples, three biological
replicates were performed. To compare CL remodeling across
tissues, we studied brain, heart, lung, and liver from C57BL/
6J(B6) wild-type male mice (4 months of age), each with four
biological replicates [27].

are approximations of the behavior of CL. Aside from a
generalization to handle dynamic data, further refinements may
include parameters for more nuanced distinctions among donor
classes. Such distinctions may be important for understanding
individual enzymes such as tafazzin, which influences the transfer
of chains from PC to CL [23]. Other important factors may
include the relative positions of PC, PE, and PG in the CL
remodeling pathway [10,41,42], molecular symmetry preferences
[43,44], or transfer of lipids among membranes. Through careful
consideration of such refinements, we expect that our mechanistic
inference method will generalize to other classes of lipids,
providing a broad approach to analyzing diseases associated with
alterations of lipid metabolism.

MDMS-SL quantification of mitochondrial lipids
Extraction and quantification of the mitochondrial lipidome for
these samples were previously described in [12,27]. Briefly, tissue
and tumor samples were harvested from mature male mice or cell
cultures, and mitochondria were isolated and purified. An aliquot
of purified mitochondria was transferred to a disposable culture
borosilicate glass tube. Internal standards were added based on the

Methods
Sample Datasets
To compare CL remodeling between normal and pathological
states, we analyzed 14 mouse brain samples, described in [12].
PLoS ONE | www.plosone.org
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Figure 4. Hierarchical clustering of FAs suggests co-regulation. For each pair of FAs, we calculated the squared correlation of their residuals
(data vs. proportional incorporation model) in the 14 brain samples. FAs were then hierarchically clustered. The chains {16:0, 18:1, 22:4} show stronger
clustering, suggesting they may respond to the same remodeling enzyme.
doi:10.1371/journal.pone.0021170.g004

assumed to be those observed within the acyl donors PC, PE, and
PG (and acyl CoA when available) in the sample.
Given the FA composition parameters in CL fPCL (a1 ),
PCL (a2 ),:::,PCL (an )g, the IID probability of the CL isomer with acyl
chain ai at position sn-1, aj at position sn-19, ak at position sn-2, and ah
at position sn-29 is defined by Equation 1:

protein concentration (in nmol/mg mitochondrial protein). Lipids
from each mitochondrial homogenate were extracted by a
modified Bligh and Dyer procedure. Each lipid extract was
reconstituted with mitochondrial protein in chloroform/methanol.
The lipids extracted were flushed with nitrogen, capped, and
stored at 220uC. Each lipid solution was diluted prior to infusion
and lipid analysis. Lipid molecular species were identified and
quantified by high resolution MDMS-SL, which is described in
detail in [30]. MDMS-SL allows for sn-1/sn-2 acyl chain
determinations for diacyl species because sn-1 and sn-2 carboxylate groups fragment at differing rates in the mass spectrometry
procedure. CL, PC, PE, PG, and acyl CoA (where available)
concentrations were normalized to probability distributions and
averaged among replicates.

0

0

sn1
sn2
P(asn1
,asn2
i ,aj
k ,ah )~PCL (ai )PCL (aj )PCL (ak )PCL (ah ) ð1Þ

MDMS-SL measures the total concentration of CL molecular
species with c carbons and d double bonds in the acyl chains. The
corresponding IID probability is summed from the isomers
matching c and d, as given by Equation 2:

Independent and identical distribution model
All of our models assume that data reflect steady state behavior
[27]. Although remodeling is dynamic, we are able to model
steady-state behavior in the same way that chemical equilibria can
be modeled without knowledge of individual reaction rates.
The IID model posits that four CL chain positions (sn-1, sn-19,
sn-2, sn-29) are independently and identically remodeled. Therefore each position is assumed to have the same FA distribution.
The concentrations of each FA chain are the parameters to be
inferred for each sample. We implemented a maximum-likelihood
approach to infer these parameters. Let V~fa1 ,a2 ,    ,an g be all
of the possible chain types in CL. The possible chain types are
PLoS ONE | www.plosone.org

yc:d ~

X

0

0

sn1
sn2
P(asn1
,asn2
i ,aj
k ,ah )

ð2Þ

isomers

The FA distribution can be found by a maximum likelihood
approach which compares yc:d with the experimentally derived
^c:d . The likelihood of observing the data
relative concentrations m
(for all CL species, S = 1..N) given the model and parameters is
assessed by the error between the predicted and observed CL
distributions, Equation 3:
8
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by Equation 5:
E~

X

(yS {^
mS )2

ð3Þ

0

The parameter set fP1CL (a1 ),P1CL (a2 ),:::,P1CL (an ),P2CL (a1 ),P2CL
(a2 ),:::,P2CL (an )g is optimized in the same manner as for the IID
model. To compare the IDD and IID, we consider the results of
the four-fold cross-validation for each model. For a given sample,
we perform the four-fold cross validation for both IDD and IID in
three runs each. Cross-validation requires a random data splitting,
so for each run we split the data differently using a random
number generator. The observed correlation in the crossvalidation is an indication of the robustness of the model. To
quantify IDD vs. IID we compare the distribution of correlation
scores (see Methods: four-fold cross-validation) for the three runs
of the two models, using a t-test.

Minimizing the error function is equivalent to maximizing a
likelihood function in which deviations from the experimental
value are distributed according to a Gaussian probability function.
We assume the variance associated with each Gaussian to be
identical, which is reasonable since this is determined by the
measurement uncertainty of the general MDMS-SL procedure for
CL. The optimal FA compositions are those that yield the
minimum error between the predicted and observed CL
distributions, as described in Equation 4:
^ CL (a1 ),P
^ CL (a2 ),:::,P
^ CL (an )g~ arg min E ðfPCL (a1 ),
fP
P

ð4Þ

PCL (a2 ),:::,PCL (an )gj^
m1 ,^
m2 , . . . ,^
mN Þ

Proportional incorporation model
The model assumes FAs from an acyl donor class are
incorporated into CL at rates proportional to their prevalence
within the donor class. This is equivalent to assuming that there
are no chain-type specificities of remodeling enzymes, i.e.
transacylases that transfer acyl chains from PC and PE would
have specificity for only the PC/PE head group and not the length
or saturation of the acyl chain. In this model, the relative
concentration of acyl chain ai in CL is a weighted sum of the
relative concentrations of the chain in each donor class (Equation
6). For PC and PE, we allow only their sn-2 acyl chains to
contribute to the acyl chain pool, consistent with prior literature
[45–47]. The weight parameters fWPC ,WPE ,WPG gindicate their
relative contributions to CL, representing the overall effect of
phospholipid concentration and transacylase/phospholipase activities [48]. For example, if the affinity weights are WPC = 0.5,
WPE = 0.25, and WPG = 0.25, this means that of all the acyl chains
making up the CL species distribution, 50% originate from PC
(sn-2) and 25% are derived from each of PE (sn-2) and PG.

We searched for optimal parameter values iteratively using
the Matlab function lsqcurvefit, with an initial condition of
1
uniform probabilities (PCL (a1 )~PCL (a2 )~:::~PCL (an )~ ),
n
and under
the constraints that PCL (a1 ),PCL (a2 ),:::,PCL (an )w0
n
P
and
PCL (ai )~1.
i~1

Least error and Pearson correlation between the optimal
predicted and observed CL probability distributions were used
to evaluate the performance of the model. These gave similar
results. We set a threshold correlation coefficient of 0.7 to decide
whether the model explained the sample data.

Four-fold cross-validation
The measurable CL molecular species were randomly divided into
four disjoint subsets of equal size. Three subsets were used to train the
model and the last was used for testing. The training-predicting
procedure was repeated four times, each time leaving out a different
subset. We then merged the predictions for the four test subsets and
compared the resulting predicted CL distribution to the observed data
using Pearson correlation coefficient. For the calculations of Table 1,
the correlation was calculated in three separate runs, where in each run
the subsets of the CL data were divided by a different randomization.

PCL (ai )~WPC PPC (ai )zWPE PPE (ai )zWPG PPG (ai )

ð6Þ

The optimal parameter values can be found by constrained
linear regression. The weight values are related to the observed CL
concentrations via:

Label permutation test
We performed a permutation test to assess the significance of
the IID model’s performance. For each sample, we generated a
randomized version of the data by permuting the labels on CL
concentrations. Our null hypothesis was that there is no
dependency between the features (FA compositions) and the
labeled values (CL species concentrations). We performed fourfold cross validation on the randomized dataset and repeated this
procedure three times using different randomized labeling. A t-test
was used to assess significance of the correlation coefficient for the
original data.

2

PPC (a1 )

PPE (a1 )

6 P (a )
6 PC 2
6
4 M
PPC (an )

PPE (a2 )
M
PPE (an )

2
^ CL (a1 )
3
P
W
6 ^
PC
7
PPG (a2 ) 7 6
7 6 PCL (a2 )
7.4 WPE 5~6
6 M
M 5
4
WPG
^ CL (an )
PPG (an )
P
PPG (a1 )

3

2

3
7
7
7
7
5

ð7Þ

Here the relative concentrations of acyl chains in each of PC sn-2,
PE sn-2, and PG (PPC ,PPE andPPC ) are experimentally deter^ CL ) is predicted using
mined. The acyl distribution within CL (P
the IID model, since experimental measurements for it were not
readily available. We use Matlab function lsqlin to infer optimal
parameter values, which minimizes the error kC :x{d k2 , with
constraints WPC ,WPE ,WPG §0 and WPC zWPE zWPG ~1. The
residual for a given chain is defined to be that chain’s component
of (d{C :x).
For B6 brain, heart, lung, and liver analysis, we additionally
include acyl CoA as an acyl donor, with weight parameter WAC

Independent and differential distribution model
This model tests whether sn-1/sn-19 and sn-2/sn-29 positions of CL
are differentially remodeled, maintaining the assumption that the four
positions of CL are independent. It is similar to the IID model, except
having distinct FA compositions: P1CL (a1 ),P1CL (a2 ),:::,P1CL (an ) for sn1/sn-19 positions and P2CL (a1 ),P2CL (a2 ),:::,P2CL (an ) for sn-2/sn-29
positions. The probability of the CL isomer with ai at position sn-1, aj
at position sn-19, ak at position sn-2, and ah at position sn-29 is defined
PLoS ONE | www.plosone.org

0

sn1
sn2
1
1
2
2
P(asn1
,asn2
i ,aj
k ,ah )~PCL (ai )PCL (aj )PCL (ak )PCL (ah ) ð5Þ

species
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This is equivalent to Equation 6, where

(Equation 8):
PCL (ai )~WPC PPC (ai )zWPE PPE (ai )zWPG PPG (ai )zWAC PAC (ai ) ð8Þ

WPC ~

(1{c)KPE ½PE
(1{c)KPC ½PCz(1{c)KPE ½PEzc
c
WPG ~
(1{c)KPC ½PCz(1{c)KPE ½PEzc

To assess the significance of model behavior, for each sample,
we randomly permuted PC, PE, and PG FA compositions (each
column of C), and generated 10000 different random datasets. An
empirical p-value was assigned for the correlation coefficient of the
true data based on the distribution of coefficients in the random
datasets.
Note that all of the models we have described are consistent
with a dynamical system at steady state. To clarify this
relationship, we describe the corresponding dynamic system for
the Proportional Incorporation model, The IID and IDD models
are analogous. The dynamic model is similar to one we previously
described in [27]. Under a model in which all four acyl chain
positions behave equivalently, the dynamics of acyl chain type a in
CL are given by the equation:

WPE ~

Supporting Information
Figure S1 Trends of deviation from the IID model.

Certain CL species appear to consistently deviate from the IID
model, notably 80:14 and 80:15 (marked with *). (A) BV2 vitro
(r = 0.8465), (B) VM M3 vitro (r = 0.5804), (C) VM (r = 0.8437) and
(D) CT2A vivo (r = 0.7245).
(TIF)

ð9Þ

Table S1 PC, PE, PG, acyl CoA, and CL concentrations
as measured by MDMS-SL.
(XLS)

z4c½CL(PPG (a){PCL (a))

Table S2 Observed and model-predicted cardiolipin
distribution for 14 samples and B6 tissues.
(XLS)

KPC andKPE are rate constants for the transfer of acyl chains
from PC or PE sn-2 chains into CL, respectively. c is the
degradation rate constant for CL. PPC (a) is the fraction of PC
chains that can be transferred into CL that are of type a (with
similar definitions for PPE (a) and PPG (a)). PCL (a) is the fraction of
all CL chains that are of type a. Since we have assumed that the
total concentration of CL (½CL) is in steady state, this obviates the
need for an explicit synthesis rate constant KPG .
The probability of chain type a in Cardiolipin is:

PCL (a)~

½aCL
~
4½CL

(1{c)KPC ½PCPPC (a)z(1{c)KPE ½PEPPE (a)zcPPG (a)
(1{c)KPC ½PCz(1{c)KPE ½PEzc

ð11Þ

To further clarify the methods, we have provided a supplementary file providing a walk-through of the methods as applied to
toy data (Methods S1).

d½aCL
~4(1{c)½KPC ½PC½CL(PPC (a){PCL (a))
dt
zKPE ½PE½CL(PPE (a){PCL (a))

(1{c)KPC ½PC
(1{c)KPC ½PCz(1{c)KPE ½PEzc

Table S3 Inferred CL acyl compositions and experimental compositions in acyl donors PG, PC sn-2, PE sn-2, and
acyl CoA.
(XLS)
Methods S1 Example illustrating the mathematical

methods described in the paper.
(DOC)
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